CLL | Understanding the Impact of COVID-19 on the Care of Patients with Chronic Lymphocytic Leukemia

published 4 months ago by Dr Neil Love

Proceedings from a CME webinar focused on COVID-19 and chronic lymphocytic leukemia. Featuring perspectives from Drs Matthew S Davids, Anthony R Mato and Jeff Sharman. Changes in chronic lymphocytic leukemia (CLL) institutional processes and procedures brought on by the COVID-19 pandemic (00:00) Case: A woman in her late 50s with a history of breast cancer requires treatment for CLL during the pandemic (9:03) Recommendations regarding the management of CLL in the COVID-19 environment (14:37) Rationale for the use of Bruton tyrosine kinase inhibitors for patients with cancer and COVID-19 (18:29) Current approach for patients with CLL requiring treatment with venetoclax/obinutuzumab (20:49) Case: A woman in her early 60s with CLL in remission after treatment with an obinutuzumab-based therapy on a clinical trial receives results of a prescribed study-related CT scan that are suspicious for COVID-19 infection (28:16) Limitations of COVID-19 testing techniques and platforms (drive-through testing, false-negative rates, et cetera) (34:31) Case: A man in his early 70s with relapsed/refractory CLL is hospitalized with COVID-19; potential role of noncancer therapeutic interventions (eg, remdesivir, anticoagulants) (39:44) Perspectives on continuing versus stopping therapy both before and during the current pandemic (47:18) Case: A man in his early 70s who is receiving PI3 kinase inhibitor therapy for relapsed/refractory CLL begins to experience symptoms of COVID-19 after his wife tests positive for the novel coronavirus (53:03) CME information and select publications

more episodes from Research To Practice | Oncology Videos